New treatments for Prader-Willi Syndrome and hemophilia; FDA fast tracks a chlamydia vaccine candidate; over-the-counter test cleared for identifying chlamydia, gonorrhea and trichomoniasis.

Department of Plant Pathology and Nematology, University of São Paulo (USP)/Luiz de Queiroz College of Agriculture (ESALQ), Av. Pádua Dias, 11, Piracicaba, São Paulo 13418-900, Brazil Department of ...

A 3.8-second improvement in time to rise (TTR) was noted compared to natural history controls, supporting a once-monthly dosing regimen. Wave Life Sciences plans to seek accelerated FDA approval ...

NPM-139 treatment resulted in nearly 20% placebo-adjusted weight loss from a single administration with expected once or twice-yearly dosing NPM-139 is a miniature ... its subdermal semaglutide ...

NPM-139 treatment resulted in nearly 20% placebo-adjusted weight loss from a single administration with expected once or twice-yearly dosing NPM ... its subdermal semaglutide implant under ...

ALAMEDA, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical ...

NanoPortal™ technology successfully delivers semaglutide, the active ingredient ... administration with expected once or twice-yearly dosing NPM-139 is a miniature, subdermal implant in ...

(MENAFN- GlobeNewsWire - Nasdaq) NanoPortalTM technology successfully delivers semaglutide ... with expected once or twice-yearly dosing NPM-139 is a miniature, subdermal implant in development ...